Metagenomi CEO Thomas Brian sells shares worth $18,873

Published 09/06/2025, 23:56
Metagenomi CEO Thomas Brian sells shares worth $18,873

In a recent transaction reported on June 6, 2025, Thomas Brian C., the Chief Executive Officer of Metagenomi, Inc. (NASDAQ:MGX), sold 10,785 shares of the company’s common stock. The shares were sold at a price of $1.75 each, totaling $18,873. Following this transaction, Brian retains ownership of 2,517,491 shares. The sale comes amid a challenging period for MGX, with the stock down over 70% in the past year. According to InvestingPro analysis, the company appears undervalued at current levels.

This sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units granted to Brian in April 2024. It is important to note that this transaction was not a discretionary trade by the CEO but rather an automatic sale for tax purposes. InvestingPro data shows management has been actively buying back shares, while maintaining a strong balance sheet with more cash than debt. Discover 10+ additional insights and detailed financial metrics with an InvestingPro subscription.

In other recent news, Metagenomi has made a significant breakthrough in gene editing technology, as reported in Nature Communications. The company has developed a compact CRISPR-associated transposase (CAST) system that successfully integrates large, therapeutically relevant genes into the human genome. This advancement could potentially revolutionize the treatment of complex genetic diseases like Wilson’s disease and cystic fibrosis. In addition, H.C. Wainwright has adjusted its outlook on Metagenomi, reducing the 12-month price target from $14 to $7 while maintaining a Buy rating. This revision comes amid heightened regulatory uncertainties following recent changes at the U.S. Food and Drug Administration. The departure of Dr. Peter Marks from the FDA is seen as a factor that may increase the hurdles for approving genetic medicines, prompting H.C. Wainwright to raise its discount rate for Metagenomi to 14%. Despite these challenges, the analyst firm still holds a positive outlook on Metagenomi’s potential. The company’s recent technological advancements are expected to pave the way for further developments in precision genetic medicines.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.